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Abstract
Background
Animal trypanosomosis caused by Trypanosoma evansi is known as “surra” and is a wide-
spread neglected tropical disease affecting wild and domestic animals mainly in South
America, the Middle East, North Africa and Asia. An essential necessity for T. evansi infec-
tion control is the availability of reliable and sensitive diagnostic tools. While DNA-based
PCR detection techniques meet these criteria, most of them require well-trained and experi-
enced users as well as a laboratory environment allowing correct protocol execution. As an
alternative, we developed a recombinase polymerase amplification (RPA) test for Type A
T. evansi. The technology uses an isothermal nucleic acid amplification approach that is
simple, fast, cost-effective and is suitable for use in minimally equipped laboratories and
even field settings.
Methodology/Principle findings
An RPA assay targeting the T. evansi RoTat1.2 VSG gene was designed for the DNA-
based detection of T. evansi. Comparing post-amplification visualization by agarose gel
electrophoresis and a lateral flow (LF) format reveals that the latter displays a higher sensi-
tivity. The RPA-LF assay is specific for RoTat1.2-expressing strains of T. evansi as it does
not detect the genomic DNA of other trypanosomatids. Finally, experimental mouse infec-
tion trials demonstrate that the T. evansi specific RPA-LF can be employed as a test-of-cure
tool.
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Conclusions/Significance
Compared to other DNA-based parasite detection methods (such as PCR and LAMP), the
T. evansi RPA-LF (TevRPA-LF) described in this paper is an interesting alternative because
of its simple read-out (user-friendly), short execution time (15 minutes), experimental sensi-
tivity of 100 fg purified genomic T. evansi DNA, and ability to be carried out at a moderate,
constant temperature (39˚C). Therefore, the TevRPA-LF is an interesting tool for the detec-
tion of active T. evansi infections.
Author summary
Neglected tropical diseases (NTDs) affecting humans and/or domestic animals severely
impair the socio-economic development of endemic areas. One of these diseases, animal
trypanosomosis, affects livestock and is caused by the parasites of the Trypanosoma genus.
The most widespread causative agent of animal trypanosomosis is T. evansi, which is
found in large parts of the world (Africa, Asia, South America, Middle East, and the Medi-
terranean). Proper control and treatment of the disease requires the availability of reliable
and sensitive diagnostic tools. DNA-based detection techniques are powerful and versatile
in the sense that they can be tailored to achieve a high specificity and usually allow the reli-
able detection of low amounts of parasite genetic material. However, many DNA-based
methodologies (such as PCR) require trained staff and well-equipped laboratories, which
is why the research community has actively investigated in developing amplification strat-
egies that are simple, fast, cost-effective and are suitable for use in minimally equipped
laboratories and field settings. In this paper, we describe the development of a diagnostic
test under a dipstick format for the specific detection of T. evansi, based on a DNA ampli-
fication principle (Recombinase Polymerase Amplification aka RPA) that meets the
above-mentioned criteria.
Introduction
Trypanosoma evansi is a haemoflagellate parasite which is closely related to T. brucei, the caus-
ative agent of human sleeping sickness and nagana in animals [1]. T. evansi is the causative
agent of “surra” or “mal de caderas”, which is the most common and widespread trypanosomal
disease of domestic and wild animals and is characterized by high morbidity and mortality.
The parasite is mechanically transmitted by biting flies and is found in many regions around
the globe [2–6]. Outbreaks of surra have been reported in all types of ungulates (camels, cattle,
buffaloes, horses, pigs, and deer) in Africa [7], Asia [8–10], Latin America [11–13] and recently
Europe [14–16]. While T. evansi is commonly known as non-infective to humans, human
infections were recently reported and confirmed in India and Vietnam, indicating that
T. evansi may be emerging as a potential human pathogen [17–20]. Control of T. evansi trypa-
nosomosis is mainly accomplished by drug treatment, but resistance of T. evansi to trypanoci-
dal compounds has been reported in Africa [21, 22] and in the far east of Asia [23].
T. evansi parasites are classified into two groups based on their kDNA minicircle type [24],
which are characterised by the presence (Type A) or absence (Type B) of the gene encoding
the RoTat1.2 variant surface glycoprotein (VSG) [25, 26]. T. evansi Type B are less commonly
found and have only been reported to occur in certain regions in Africa [27–32]. In contrast,
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T. evansi Type A are widespread. Many diagnostic methods are available to detect T. evansi
infections and include parasitological, serological, and molecular assays [33]. While some
methods detect both T. evansi Types A and B, others are specific to one of both types. Conven-
tional blood smear examination technique is widely used in the field and detects both T. evansi
Type A and B. However, it can only diagnose clinical stages of infection and not latent or
chronic infection [34]. In addition, it is time consuming and requires both the presence of
microscopy equipment and specifically trained personnel at the screening site. To overcome
these shortcomings, the T. evansi card agglutination test (CATT/T. evansi) was developed. It is
a standard test for epidemiological field studies of T. evansi Type A since it is based on the use
of the T. evansi RoTat 1.2 VSG antigen as an agglutination agent for host antibodies [35]. The
advantage of this technique is that it is fast, easy to execute and suitable for field diagnosis. The
main disadvantage of the technique is the lack of discrimination between previous exposure
and current infections. Indeed, the host antibodies that drive the reaction can be a result of an
active infection, a past infection, repeated exposure without necessarily initiation of successful
infection, or even polyclonal B cell activation by other infectious agents such as helminths
[36].
The diagnosis of trypanosomosis has been improved by the development and application of
DNA-based techniques such as PCR, which is a very sensitive and effective method for the
detection of chronic infections or prepatent period of disease [37, 38]. The DNA of killed try-
panosomes does not remain in the blood for more than 24 to 48 hours, thus PCR-based assays
are highly suitable for the detection of active infections [39]. Several genes have been investi-
gated as targets for the PCR-based diagnosis of T. evansi; these include the RoTat1.2 VSG gene
(Type A specific) [40–42], ribosomal DNA [43], a region from r-RNA internal transcribed
spacer 1 (ITS-1) [44], the gene encoding the invariant surface glycoprotein ISG-75 [45], and
the VSG JN 2118Hu gene (Type B specific) [26, 28, 46, 47]. The drawback of PCR-based meth-
ods is that they require well-trained and experienced personnel and a laboratory environment
suitable for correct protocol execution. Hence, they are difficult to deploy and maintain under
most field conditions. An interesting alternative to PCR is the so-called Recombinase Polymer-
ase Amplification (RPA) [48]. The reaction mechanism of RPA has been reviewed elsewhere
[49, 50] and is summarized in Fig 1 (the figure legend contains a detailed explanation of the
RPA reaction). This isothermal nucleic acid amplification technology is simple, fast, cost-effec-
tive and is suitable for minimally equipped laboratories as well as for use in the field [51].
Hence, RPA is especially useful in infectious disease diagnostics and epidemiological studies
[52–55]. The RPA reaction can be completed in 10 to 20 minutes at temperatures between
24˚C to 45˚C [56]. The amplification product can be visualized by gel electrophoresis or in
real-time by the inclusion of a nucleic acid dye. The specificity and sensitivity of RPA are typi-
cally enhanced by probe-based methods, which (depending on the type of probe) allow ampli-
con detection based on fluorescence or a lateral flow (LF) assay [48]. To date, RPA has been
successfully applied for the detection of bacteria [57, 58], foodborne pathogens [59, 60], para-
sites [61, 62], and viruses [63, 64].
In this present study, we describe the development of the first recombinase polymerase
amplification lateral flow assay for the detection of active Type A T. evansi infections (TevR-
PA-LF). The T. evansi RoTat1.2 VSG gene was chosen as the target for the TevRPA-LF for the
following reasons: i) to ensure high specificity of the TevRPA-LF for T. evansi as this parasite is
closely related to T. brucei, ii) T. evansi Type A are most commonly encountered and wide-
spread, and iii) to allow comparison with the previously described PCR targeting the T. evansi
RoTat1.2 VSG gene [33]. We demonstrate that the TevRPA-LF assay is highly specific for T.
evansi since no cross-reactions with the closely related parasite T. brucei could be observed. In
addition, we have tested the TevRPA-LF in an experimental mouse model and demonstrate
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that it can be used as a test-of-cure tool. The TevRPA-LF described here has a processing time
of 15 minutes and can be performed at a constant temperature of 39˚C. Combined with the
simplicity, robustness and reliability of the RPA-FL principle, the findings presented in this
paper show that the TevRPA-LF can be a promising tool for the detection of active T. evansi
infections.
Materials and methods
Ethics statement
All experiments, maintenance and care of the mice complied with the European Convention
for the Protection of Vertebrate Animals (ECPVA) used for Experimental and Other Scientific
Fig 1. Schematic representation of the TevRPA-LF. A: RPA-based generation of a T. evansi specific RoTat1.2 VSG amplicon for
detection by a lateral flow (LF) assay. Step 1: two oligonucleotide primers (TevRPA-Fw and TevRPA-Rv-biotin) form a complex with
the recombinase. Step 2: the primer-recombinase complexes invade the homologous sequences on the target DNA. Step 3: A DNA
polymerase with a strand displacement activity performs amplification of the target sequence under isothermal conditions, resulting
in the generation of a biotinylated amplicon. Step 4: the generated amplicons are again invaded by primer-recombinase complexes in
a self-perpetuating cycle fueled in ATP by creatine kinase. Step 5: an oligonucleotide (FAM-probe) carrying a 5’ FAM tag, a spacer
sequence and a 3’ blocking group forms a complex with the recombinase and invades the biotinylated amplicon generated in the
previous steps. Step 6: only when the FAM-probe has successfully invaded the biotinylated amplicon and bound its complementary
sequence, can the Nfo endonuclease bind and cleave the spacer region and 3’ blocking group. Step 7: after removal of the 3’ region of
the FAM probe, the Nfo endonuclease dissociates. This allows the DNA polymerase to employ the cleaved FAM-probe as a forward
primer. Together with the biotinylated reverse primer (TevRPA-Rv-biotin) this leads to the formation of an amplicon bearing both
the FAM and biotin tags. B: Read-out of the RPA via LF. The FAM- and biotin-tagged RPA product is mixed with the LF buffer,
loaded onto the sample pad and is transported to the adsorbent pad through capillary flow. The RPA product is first bound by gold-
labeled rabbit anti-FAM antibodies and later captured by a streptavidin-coated test line (TL). The control line (CL) is coated with
anti-rabbit antibodies. While a valid negative test only contains a reddish band at the CL, a valid positive test will display bands at
both the TL and CL.
https://doi.org/10.1371/journal.pntd.0008044.g001
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Purposes guidelines (CETS n˚ 123) and were approved by the Ethical Committee for Animal
Experiments (ECAE) at the Vrije Universiteit Brussel (Permit Number: 14-220-31).
Preparation of purified genomic DNA
Total genomic DNA of the different parasites used in this study (Table 1) was extracted and
purified from infected mouse whole blood using a DNeasy Blood & Tissue Kit (Qiagen, Ger-
many) according to the manufacturer’s instructions. The DNA was eluted in 50 μl nuclease-
free water and stored at -20˚C until further use. The concentration and quality of the purified
DNA were determined by gel electrophoresis (1% agarose gel run in TBE buffer at 110 V for
30 min) and spectrophotometric analysis (measurement of the absorbance at 260 nm, A260;
examination of the ratio of the absorbances at 260 nm and 280 nm, A260/A280; performed on a
NanoDrop-2000/2000c).
Preparation of crude genomic DNA
Genomic DNA was robustly extracted by boiling. Briefly, 50 μl of blood was mixed with 10 μl
nuclease-free water (Thermofisher). The sample was heated at 100˚C for 5 minutes followed
by centrifugation at 20000 g for 5 minutes, and the supernatant was applied as a crude DNA
template. The DNA template was kept at -20˚C until use.
RPA primers and probes design
The primers and probes were manually designed based on the gene sequence of the Rode Try-
panozoon antigenic type 1.2 VSG (RoTat 1.2 VSG) of T. evansi (GenBank accession code:
AF317914.1). The NCBI’s nucleotide BLAST tools combined with Primer 5 were used to
search for primers specific to T. evansi without significant overlap with other genomes. The
TwistAmp LF Probe oligonucleotide backbone includes a 5’-antigenic label FAM group, an
internal abasic nucleotide analogue ‘dSpacer’ and a 3’-polymerase extension blocking group
C3-spacer. The details of the primers and probes used are given in Table 2.
Development and optimization of the TevRPA assay
The RPA reactions were conducted with the TwistAmp Basic kit (TwistDx, Cambridge, UK).
A 47.5 μl reaction mixture containing the following components was prepared in a 1.5 ml
tube: 2.4 μl of both forward and reverse primers (final concentration: 480 nM), 29.5 μl
Table 1. Characteristics of trypanosomatid parasites used in this study.
Strain Host Country
T. evansi RoTat1.2 Water buffalo Indonesia
T. evansi STIB816 Camel China
T. evansi ITMAS180697 Water buffalo Vietnam
T. evansi 020499B Horse Columbia
T. evansi CAN86K Dog Brazil
T. evansi ITMAS060297 Camel Kazakhstan
T. evansi ITMAS050399C Camel Morocco
T. congolense Tc13 Cow Kenya
T. vivax TV700 Cattle Nigeria
T. brucei AnTat1.1 Bushbuck Uganda
L. donovani Ldl82 Human Ethiopia
https://doi.org/10.1371/journal.pntd.0008044.t001
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rehydration buffer supplied by the TwistAmp Basic kit, 12.2 μl nuclease-free water and 1 μl T.
evansi purified genomic DNA (concentration of 120 ng μl−1). The reaction mixture was then
transferred to the kit’s reaction tubes containing lyophilized enzyme pellet. Next, 2.5 μl magne-
sium acetate (MgAc; final concentration of 14 nM) was carefully pipetted onto the reaction
tube lids. This was followed by a brief vortex and spin to mix MgAc with the RPA reaction
mixture. The tubes were incubated in a thermocycler. To pinpoint the most optimal condi-
tions for the TevRPA, the samples were incubated at different reaction temperatures (25˚C,
30˚C, 35˚C, 37˚C, 39˚C, 41˚C, 43˚C, 45˚C, and 50˚C) and for different durations (5 minutes,
10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes and 40 minutes).
Reactions were halted by placing the tubes on ice. The amplified products were first purified
using the GenElute PCR Clean-Up kit (Sigma-Aldrich) and visualized on a 2% agarose gel.
Development and optimization of the TevRPA-LF
LF-RPA assays were performed following the indications provided in the TwistAmp nfo kit
(TwistDx, Cambridge, UK). Briefly, the RPA reaction was assembled as described above
(Materials and Methods subsection ‘Development and optimization of the TevRPA assay’)
with the exception of the addition of 2.1 μl of both forward and reverse primers (final concen-
tration: 420 nM) and 0.6 μl probe (final concentration: 120 nM) to the reaction mixture. The
amplified DNA was detected using LF strips (Milenia Hybridtech 1, TwistDx, Cambridge,
UK) following the instructions indicated in the kit. Briefly, 1 μl of the amplified product was
diluted with 99 μl LF buffer. Ten μl of this diluted sample was then loaded on the sample appli-
cation area according to the manufacturer’s instructions. The final result was visually read out
after incubation for 2 minutes at room temperature. A testing sample was considered positive
when both the detection line (biotin-ligand line) and the control line (anti-rabbit antibody
line) were visible. A testing was considered negative when only the control line was visible (Fig
1). The amplicons could be analyzed on a 2% agarose gel after purification with the GenElute
PCR Clean-Up kit (Sigma-Aldrich) to further confirm the testing result.
Evaluation of sensitivity and specificity of the TevRPA-LF
The specificity of the TevRPA-LF was assessed by employing 20 ng of purified genomic DNA
isolated from various parasites (Table 1). Samples containing only nuclease-free water were
used as negative controls.
The sensitivity of the TevRPA-LF was tested by employing the following concentrations of
T. evansi purified genomic DNA as templates for the RPA reaction: 10 ng μl−1, 1 ng μl−1, 100
pg μl−1, 10 pg μl−1, 1 pg μl−1, 100 fg μl−1, 10 fg μl−1 and 1 fg μl−1. The results were analyzed by
lateral flow and agarose gel electrophoresis.
Table 2. Primers and probes employed in this study.
Assay type Primer name Oligonucleotide (5’-3’) Reference
TevRPA TevRPA-Fw
TevRPA-Rv
CACCGAAGCAAGCGCAGCAAGAGGGTTAGCA
GTAGCTGTCTCCTGGGGCCGAGGTGTCATAG
This study
TevRPA-LF TevRPA-Rv-biotin
FAM-Probe 1
FAM-Probe 2
[Biotin]GTAGCTGTCTCCTGGGGCCGAGGTGTCATAG
[6F]TCTGCCCGCAGTTGCCTATGGCGGCGAAGT[dS]GCAGGGGCGATTTCAT[C3]
[6F]CTAAAATTTCTAAAGCACGCGGTTGGCAACA[dS]CAAGTTTGTGTGGGC[C3]
This study
PCR RoTat1.2 Fw
RoTat1.2 Rv
GCGGGGTGTTTAAAGCAATA
ATTAGTGCTGCGTGTGTTCG
[40]
6F stands for 6FAM, dS for dSpacer, and C3 for C3-spacer.
https://doi.org/10.1371/journal.pntd.0008044.t002
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Comparison between TevPCR and TevRPA-LF in an experimental mouse
infection model
C57BL6/C mice (bred in-house, 8 weeks old) were divided in two groups of six individuals. In
each group, five mice were inoculated intraperitoneally with 2000 T. evansi (Rotat 1.2 strain)
parasites in 200 μl of PSG buffer (36.4 mM NaCl, 3.12 mM NaH2PO4, 47.5 mM Na2HPO4 and
85.2 mM glucose, pH 8). The remaining mouse in each group was used as a negative control
and was not infected. The mice were bled at different times post-infection. The mice in Group
1 were bled at days 1, 3, 5 and 6 post-infection. The animals in Group 2 were bled at days 0, 2,
4, 6, 8, 10 and 12 post-infection. All individuals from Group 2 were treated with Berenil (40
mg per kg), administered intraperitoneally at day 5 post-infection. For both groups, at each
time point, 102.5 μl of whole blood was collected from the tail of each individual using nucle-
ase-free tubes with 30 ml heparinized saline (10 units/ml; Sigma-Aldrich) to prevent coagula-
tion. 2.5 μl of the collected blood was used to follow-up mice parasitemia by diluting the
sample 200-fold (during high parasitemia periods) and 100-fold (during low parasitemia peri-
ods) in PSG buffer and counting the parasites under the light microscope. The rest of the col-
lected blood (100 μl) was split into two parts to evaluate the samples using the TevPCR and
TevRPA-LF. Fifty μl of collected blood was employed to prepare purified genomic DNA for
the TevPCR, whereas the remaining 50 μl of collected blood was used to obtain crude genomic
DNA for the TevRPA-LF. The TevPCR was performed as described in [40] with the following
modifications: the amount of purified genomic DNA as starting material (250 ng vs. 3000 ng)
and the addition of 10% DMSO to the reaction mixture.
Results and discussion
Development and optimization of the TevRPA
The first requirement of the TevRPA-LF is a high specificity for the detection of T. evansi. This
parasite is closely related to T. brucei and thus the selection of an appropriate nucleotide
sequence that is unique to T. evansi is crucial. This is the case for a specific region (bp 1 to bp
1300) of the T. evansi RoTat1.2 VSG gene [40–42], which forms the target of the TevRPA-LF
for T. evansi detection (Fig 1). This limits the use of the TevRPA-LF described here to the
detection of Type A T. evansi, and not Type B. Based on this particular region, a primer pair
was designed for the TevRPA such that the resulting amplicon does not exceed 500 bp (as sug-
gested by the RPA manufacturer instructions). As can be seen from Fig 2A, an RPA with this
primer pair (initially incubated at 37˚C for 30 minutes) on T. evansi purified genomic DNA
extracted from infected mice blood yields an amplicon of around 289 bp. The reaction was
also performed on genomic DNA purified from a naive mouse to exclude the possible lack of
specificity due to cross-reactivity. No amplification could be observed in this negative control
sample (Fig 2A).
Next, the assay conditions were optimized by allowing the RPA reaction to proceed at vari-
ous incubation temperatures and amplification times. First, a range of incubation tempera-
tures between 25˚C and 50˚C were tested at a constant amplification time of 30 minutes. As
can be seen from Fig 2B, 39˚C represents the most optimal incubation temperature as it pro-
duces the highest amount of amplicon. In a second phase, the RPA was performed at a con-
stant incubation temperature of 39˚C while varying the amplification times from 5 to 40
minutes in 5 minute increments (Fig 2C). Although the TevRPA can be performed within 10
minutes, longer incubation times clearly yield a higher signal. The amplification time of 15
minutes was selected in an effort to maintain a balance between providing maximum sensitiv-
ity and obtaining a minimal reaction time. In conclusion, these experiments demonstrate that
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the TevRPA may be reliably performed with an amplification time of 15 minutes and an
incubation temperature of 39˚C. These conditions were maintained for all subsequent
experiments.
The TevRPA can be translated into a specific and sensitive TevRPA-LF
The visualization of the RPA amplicon via agarose gel electrophoresis requires an additional
purification step to avoid smeared bands on the gel due to the presence of enzymes and crowd-
ing agents [50]. This additional handling step is not necessary if the assay’s read-out is per-
formed via a lateral flow (LF) device [48, 49]. However, the translation of an RPA to an
RPA-LF necessitates the addition of a labeled probe to the RPA reaction mixture and the bioti-
nylation of the RPA reverse primer (Fig 1). Two candidate probes were screened for their
potential to generate an RPA-LF for T. evansi detection (from here on referred to as TevR-
PA-LF). Although both probes gave rise to positive signals when tested on T. evansi purified
genomic DNA in both agarose gel electrophoresis and lateral flow detection formats, probe 1
clearly generates false positives while probe 2 does not (Fig 3A, right and left panels, respec-
tively). Therefore, probe 2 was selected to be incorporated in the RPA assay to allow post-
amplification detection of the amplicon via the TevRPA-LF.
Next, the specificity of the TevRPA-LF was evaluated by employing purified genomic DNA
of various Trypanosoma and one Leishmania species as starting material for the amplification
Fig 2. Optimization of the TevRPA. A: Initial RPA incubated at 37˚C for 30 minutes on various samples. Lane 1, T. evansi purified
genomic DNA; Lane 2, naïve mouse purified genomic DNA; Lane 3, sample without any template; Lane 4, RPA kit positive control;
Lane 5, RPA kit negative control. B: RPA reaction on T. evansi purified genomic DNA incubated at different temperatures for a
constant time of 30 minutes. C: RPA reaction on T. evansi purified genomic DNA incubated at a constant temperature of 39˚C for
various times. In all panels Lane M indicates the molecular mass marker, whereas Lane N in panels B and C represents a negative
control sample (no template DNA).
https://doi.org/10.1371/journal.pntd.0008044.g002
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reaction. Only T. evansi genomic DNA resulted in visible bands at the test line, while the geno-
mic material of other trypanosomatids did not result in any detection (Fig 3B).
Finally, the detection limit of the TevRPA-LF was compared to the sensitivity of amplicon
visualization via agarose gel electrophoresis by performing the TevRPA on a 10-fold dilution
Fig 3. Read-out of the TevRPA via a lateral flow assay (TevRPA-LF) and agarose gel electrophoresis. A: Selection of a suitable
probe for the development of the TevRPA-LF. P1 and P2 refer to FAM probes 1 and 2, respectively. Lane 1, T. evansi purified
genomic DNA; Lane 2, naïve mouse purified genomic DNA. B: Assessment of the specificity of the TevRPA-LF. Lanes 1-7, various T.
evansi strains as listed in Table 1; Lane 8, T. congolense; Lane 9, T. vivax; Lane 10, T. brucei; Lane 11, L. donovani. C: Comparison of
the sensitivities of the TevRPA by a lateral flow assay and agarose gel electrophoresis. Lanes 1-8, 10-fold dilution series of T. evansi
purified genomic DNA starting at 10 ng μl−1 (1 μl was loaded onto the gel). Lane 1, 10 ng; Lane 2, 1 ng; Lane 3, 100 pg; Lane 4, 10 pg;
Lane 5, 1 pg; Lane 6, 100 fg; Lane 7, 10 fg; Lane 8,1 fg. All panels display the read-out of the TevRPA by a lateral flow assay (left) and
agarose gel electrophoresis (right). In all panels Lane M indicates the molecular mass marker, whereas Lane N represents a negative
control sample (no template DNA). CL and TL refer to the control and test lines, respectively.
https://doi.org/10.1371/journal.pntd.0008044.g003
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series ranging from 10 ng to 1 fg T. evansi purified genomic DNA per reaction (Fig 3C). When
visualized using agarose gel electrophoresis, the lowest amount of genomic DNA that produces
an amplicon that can be detected is 100 pg. In contrast, the TevRPA-LF allows amplicon detec-
tion at an amount of 100 fg genomic DNA, which is 1000-fold more sensitive compared to aga-
rose gel electrophoresis. The loss of sensitivity during post-amplification visualization via
agarose gel electrophoresis is most probably related to the additional required purification step
[65]. Hence, for the TevRPA, the extra purification step comes at the cost of sensitivity, which
advocates the use of the TevRPA-LF over the TevRPA followed by agarose gel electrophoresis.
The TevRPA-LF can detect active T. evansi infections in an experimental
mouse model
Next, the TevRPA-LF was evaluated for its potential to differentiate between ongoing and past
infections in an experimental mouse model. In this experiment, C57BL/6 mice infected with
T. evansi RoTat1.2 were divided into two groups and the presence of parasites was analyzed by
microscopy, the previously described TevPCR [40] and the TevRPA-LF at various time points.
Group 1 was left untreated, while Group 2 was treated with Berenil at 5 days post-infection.
As shown in Figs 4 and 5, all three techniques yielded identical results for most of the col-
lected samples. A discrepancy between the detection methods was only observed at 3 days
post-infection in Group 1; while parasites could only be detected in 3 out of 5 mice by micros-
copy, all samples were found to be positive when tested by the TevPCR and TevRPA-LF (Figs
4A and 5A). It is noteworthy to mention that in Group 1 only 4 samples from infected mice
were available for testing at day 6 post-infection due to the premature death of one mouse. As
expected, all infected mice in Group 1 succumbed to the infection at 7 days post-infection. In
contrast, the mice in Group 2 survived day 7 post-infection indicating successful parasite clear-
ance after Berenil treatment at day 5 post-infection. One mouse in Group 2 did not display
Fig 4. Evaluation of the TevRPA-LF as a test-of-cure tool in T. evansi infections in mice. A: C57BL/6 mice were infected with T.
evansi RoTat1.2 (n = 5) and the presence of parasites was monitored over the course of the infection by microscopy (top panel), the
TevPCR (middle panel, performed on parasite genomic DNA purified from the collected blood samples), and TevRPA-LF (bottom
panel, executed on crude parasite genomic DNA extracted from the collected blood). The results are displayed as the percentages of
mice that scored positive or negative as determined by the above-mentioned techniques. B: C57BL/6 mice infected with T. evansi
RoTat1.2 (n = 5) were treated with Berenil at 5 days post-infection. The presence of parasites was followed by microscopy, the
TevPCR and the TevRPA-LF throughout the experiment. The panels and color codes are the same as for panel A. The TevPCR and
TevRPA-LF read-outs are shown in Fig 5.
https://doi.org/10.1371/journal.pntd.0008044.g004
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any signs of infection (4 days post-infection) and was scored as negative by all three methods.
Importantly, no amplicons could be detected post-treatment by either the previously validated
TevPCR [40–42] or the TevRPA-LF described in this work (Figs 4B and 5B). This demon-
strates that the TevRPA-LF is a suitable ‘test-of-cure’ assay. While both the TevPCR and TevR-
PA-LF display identical positive and negative score rates under these experimental conditions,
the advantage of the TevRPA-LF is that it is effective when performed with crude genomic
Fig 5. TevPCR and TevRPA-LF read-outs. The TevPCR (bottom panels) and TevRPA-LF (upper panels) read-outs displayed in Fig
4. A: TevPCR and TevRPA-LF results for the mouse infection trial of Group 1 mice (corresponds to the data set shown in Fig 4A). B:
TevPCR and TevRPA-LF results for the mouse infection trial of Group 2 mice (corresponds to the data set shown in Fig 4B). In all
panels Lane M indicates the molecular mass marker, Lanes 1-6 indicate the individual mice (mouse 6 was used as a negative control
within each data set and was not infected), Lane N is a negative control sample (no template DNA) and Lane P is the positive control
(T. evansi purified genomic DNA). CL and TL refer to the control and test lines, respectively.
https://doi.org/10.1371/journal.pntd.0008044.g005
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DNA, whereas execution of the TevPCR requires additional purification of the isolated geno-
mic DNA.
Conclusion
T. evansi is the one of the most widespread causative agents of animal trypanosomosis in the
world [6]. An essential part of parasite control is the availability of reliable, quick, and user-
friendly diagnostic methods. In this paper, we have described the development of a TevR-
PA-LF, a test that specifically detects active Type A T. evansi infections by amplifying a region
in the T. evansi RoTat1.2 VSG gene. While the T. evansi RoTat1.2 VSG is also targeted by the
T. evansi CATT [35] and TevPCR [40–42] at the protein and DNA levels, respectively, the
TevRPA-LF presents some interesting advantages: i) compared to antibody-based tests (RoTat
1.2 CATT, Surra Sero K-Set, and T. evansi trypanolysis) the TevRPA-LF can be employed to
detect active parasitaemia and also serves as a test-of-cure tool since it is not hampered by the
presence of infection-induced antibodies that could be the result of past infections or repeated
parasite exposure without active infection and ii) the TevRPA-LF combines the RPA format
with a dipstick read-out, which outperforms a regular PCR in terms of user-friendliness and
field applicability. While it can be argued that LAMP [66] offers the same advantage, the pro-
posed LF format offers an advantage in terms of user friendliness as it visually resembles an
antibody-test format that is already in place, while offering the advantage of detecting active
infections. Based on the above-mentioned findings, the newly developed TevRPA-LF pre-
sented in this paper provides a proof-of-concept with the potential of becoming a valid alterna-
tive for currently used screening tools. Its further development will require an additional
evaluation of its performance in both experimental and clinical animal infection models.
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